Resistance to Gemcitabine in a Lymphoma Cell Line Resistant to Fas-mediated Apoptosis

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 851-857

  Meli, Maria ^a   Tolomeo, Manlio ^b   D'Alessandro, Natale ^a   Grimaudo, Stefania ^a   Notarbartolo, Monica ^a   Papoff, Giuliana ^c   Ruberti, Giovina ^c   Rausa, Luciano ^a   Dusonchet, Luisa ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

Author keywords

Apoptosis; Caspases; Drug resistance; Fas FasL system; Gemcitabine

Indexed keywords

ACETYLASPARTYLGLUTAMYLVALYLASPARTALDEHYDE; ACETYLTYROSYLVALYLASPARTALDEHYDE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; DEOXYCYTIDINE KINASE; FAS LIGAND; GEMCITABINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CLONE; CELL ISOLATION; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOMA; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FAS LIGAND PROTEIN; HUMANS; LYMPHOMA, T-CELL; MEMBRANE GLYCOPROTEINS;

EID: 2442438979     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Plunkett W, Huang P, Xu Y, Heinemann V, Grunewald R and Gandhi V: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22: 3-10, 1995.
2. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM and Peters GJ: Development and molecular characterization of a 2′2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54: 4138-4143, 1994.
3. Goan YG, Zhou B, Hu E, Mi S and Yen Y: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204-4207, 1999.
4. Neff T and Blau CA: Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 24: 1340-1346, 1996.
5. Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G and Simon MM: Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br J Cancer 74: 172-177, 1996.
6. Huang P and Plunkett W: Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36: 181-188, 1995.
7. Tolomeo M and Simoni D: Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem-Anti-Cancer Agents 2: 387-398, 2002.
8. Gruss HJ: Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 26: 143-159, 1996.
9. Yischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME: Cytotoxicity-dependent APO-1 (FAS/CD95) associated protein form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588, 1995.
10. Antoku K, Liu Z and Johnson DE: Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia 11: 1665-1672, 1997.
11. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K and Debatin KM: Cross-resistance of Fas- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90: 3118-3129, 1997.
12. Panvichian R, Orth K, Day ML, Pilat MJ and Pienta KJ: Paclitaxel-associated multinucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 58: 4667-4672, 1998.
13. Friesen C, Herr I, Krammer PH and Debatin KM: Involvement of the Fas (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2: 574-577, 1996.
14. Fulda S, Sieverts H, Friesen C, Herr I and Debatin KM: The Fas (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57: 3823-3829, 1997.
15. Houghton JA, Harwood FG and Tillman DM: Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA 94: 8144-8149, 1997.
16. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A and Green DR: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1: 543-551, 1998.
17. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH and Galle PR: Drug-induced apoptosis in hepatoma cells is mediated by the Fas (APO-/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403-443, 1997.
18. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshow WC, Leibson PJ and Kaufmann SH: Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90: 935-943, 1997.
19. Ferrari D, Stepczynska A, Los M, Wesselborg S and Schulze-Osthoff K: Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J Exp Med 188: 979-984, 1998.
20. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, Froelich CJ and Tschopp J: FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 161: 3936-3942, 1998.
21. McGahon AJ, Costa Pereira AP, Daly L and Cotter TG: Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 101: 539-547, 1998.
22. Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D'Alessandro N, Papoff G, Ruberti G and Rausa L: The Fas/Fas ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ 5: 735-742, 1998.
23. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R and Greil R: Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 57: 3331-3334, 1997.
24. Cascino I, Papoff G, De Maria R, Testi R and Ruberti G: Fas/Apo-1 (Fas) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 156: 13-17, 1996.
25. Duke RC and Cohen JJ: Morphological and biochemical assays of apoptosis. In: Current Protocols in Immunology (Coligan JE and Kruisbeak AM, eds). New York, John Wiley & Sons. 1992, p 3.17.1.
26. Darziynkiewick Z, Bruno S, Del Bino G, Gorczyca W, Holz MA, Lassota P and Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-798, 1992.
27. Arnèr ESJ, Spasokoukotskaja T and Eriksson S: Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 188: 712-718, 1992.
28. Cifone MG, Roucaioli P, De Maria R, Camarda G, Santoni A, Ruberti G and Testi R: Multiple pathways originate a the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J 14: 5859-5868, 1995.
29. Plagemann PGW, Marz R and Wohlhueter RM: Transport and metabolism of deoxycytidine and 1-β-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Res 38: 978-989, 1978.
30. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K and Guldberg P: Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92: 3018-3024, 1998.
31. Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY and Yoo NJ: Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59: 3068-3072, 1999.
32. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY and Yoo NJ: Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18: 3754-3760, 1999.
33. Van Doorn R, Dijkman R, Vermeer MH, Starink TM, Willemze R and Tensen CP: A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 62: 5389-5392, 2002.
34. Griffith DA and Jarvis SM: Nucleoside and nucleobase trasport systems of mammalian cells. Biochim Biophys Acta 1286: 153-181, 1996.
35. Boleti H, Coe IR, Baldwin SA, Young JD and Cass CE: Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacol 36: 1167-1179, 1997.
36. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR and Cass CE: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357, 1998.
37. Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM and Peters GJ: Collateral sensitivity to gemcitabine (2′,2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM26-resistant variants of human small cell-lung cancer cell lines. Biochem Pharmacol 61: 1401-1408, 2001.